全球首创！亚辉龙中枢神经疾病检测领域实现重大突破

Core Insights - Aihuilong (688575.SH) has received approval from the Guangdong Provincial Drug Administration for its self-developed soluble CD146 detection kit (chemiluminescence method), marking a significant breakthrough in the detection of central nervous system diseases [1] - Aihuilong is the first company globally to possess a soluble CD146 detection kit for cerebrospinal fluid, bringing its total number of domestic chemiluminescent reagent products to 173 [1] Group 1: Clinical Significance - Research indicates that the concentration of soluble CD146 (sCD146) in cerebrospinal fluid is significantly elevated in patients with central nervous system autoimmune inflammatory demyelinating diseases, such as multiple sclerosis (MS) and neuromyelitis optica [2] - Traditional laboratory testing methods for these diseases have limitations, including complex procedures and long detection cycles, which Aihuilong's innovative chemiluminescence method aims to overcome by simplifying operations and enhancing sensitivity and specificity [2][3] - The sCD146 level in cerebrospinal fluid has shown a strong correlation with various inflammatory factors, making it a crucial auxiliary diagnostic marker for early and precise diagnosis of these diseases [2] Group 2: Technological Innovation - The soluble CD146 detection kit represents a groundbreaking technological achievement developed in collaboration with Professor Yan Xiyun, a renowned academician and expert in nanobiology [4] - This innovation not only transforms the diagnostic approach for central nervous system autoimmune inflammatory demyelinating diseases but also strengthens China's international leadership in this diagnostic field [4] - Aihuilong is conducting multi-center studies with Xuanwu Hospital to establish new diagnostic technologies and solutions based on sCD146, with plans to expand its application in various medical fields, including obstetrics, autoimmune diseases, cardiovascular diseases, and oncology [4]